$1.66
-0.045-2.64%
Last update: Nov 11, 4:00 PM
XTL Biopharmaceuticals Ltd
XTLBNASDAQ
XTL Biopharmaceuticals fell 58.1% from $3.96 to $1.66, behind the S&P 500's +9.8%. Its worst day was May 7 (−17.8%), and its low came Nov 6 at $1.55.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.01 was reported on $517,000.00 revenue.
+3.2% · S&P 500 −0.1%
XTL Biopharmaceuticals closed at its highest level of the year, 8.1% above where the year started.
Story events cover the past 12 months · Times ET
+56.7%, the year's best day · S&P 500 −0.2%
XTL Biopharmaceuticals shares rose 27.9%, while the S&P 500 fell 0.5%.
+27.9% · S&P 500 −0.5%
XTL Biopharmaceuticals shares rose 51.5%, while the S&P 500 fell 0.0%.
+51.5%, on 114M shares, the year's heaviest volume · S&P 500 0.0%
EPS of $-0.00 was reported on $0.00 revenue.
−8.8% · S&P 500 −0.1%
XTL Biopharmaceuticals closed at its lowest level of the year, 60.9% below where the year started.
−6.6% · S&P 500 +0.3%
Where it ended: a close of $1.66 on Nov 11, 2026. Up next: H1 2026 earnings on Dec 29, 2026.
Nothing in the past 12 months.
All XTLB analyst actionsNothing in the past 12 months.
All XTLB dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for XTLB and SPY from Benzinga historical bars. Not investment advice.
